These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

747 related items for PubMed ID: 9513602

  • 1. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW, Murray DK, Elliott WL, Fry DW, Howard CT, Nelson JM, Roberts BJ, Vincent PW, Showalter HD, Winters RT, Denny WA.
    J Med Chem; 1998 Feb 26; 41(5):742-51. PubMed ID: 9513602
    [Abstract] [Full Text] [Related]

  • 2. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Thompson AM, Murray DK, Elliott WL, Fry DW, Nelson JA, Showalter HD, Roberts BJ, Vincent PW, Denny WA.
    J Med Chem; 1997 Nov 21; 40(24):3915-25. PubMed ID: 9397172
    [Abstract] [Full Text] [Related]

  • 3. Tyrosine kinase inhibitors. 12. Synthesis and structure-activity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor.
    Rewcastle GW, Bridges AJ, Fry DW, Rubin JR, Denny WA.
    J Med Chem; 1997 Jun 06; 40(12):1820-6. PubMed ID: 9191958
    [Abstract] [Full Text] [Related]

  • 4. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM.
    J Med Chem; 1998 Aug 13; 41(17):3276-92. PubMed ID: 9703473
    [Abstract] [Full Text] [Related]

  • 5. Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor.
    Rewcastle GW, Palmer BD, Thompson AM, Bridges AJ, Cody DR, Zhou H, Fry DW, McMichael A, Denny WA.
    J Med Chem; 1996 Apr 26; 39(9):1823-35. PubMed ID: 8627606
    [Abstract] [Full Text] [Related]

  • 6. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
    Smaill JB, Palmer BD, Rewcastle GW, Denny WA, McNamara DJ, Dobrusin EM, Bridges AJ, Zhou H, Showalter HD, Winters RT, Leopold WR, Fry DW, Nelson JM, Slintak V, Elliot WL, Roberts BJ, Vincent PW, Patmore SJ.
    J Med Chem; 1999 May 20; 42(10):1803-15. PubMed ID: 10346932
    [Abstract] [Full Text] [Related]

  • 7. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD, Sercel AD, Leja BM, Wolfangel CD, Ambroso LA, Elliott WL, Fry DW, Kraker AJ, Howard CT, Lu GH, Moore CW, Nelson JM, Roberts BJ, Vincent PW, Denny WA, Thompson AM.
    J Med Chem; 1997 Feb 14; 40(4):413-26. PubMed ID: 9046331
    [Abstract] [Full Text] [Related]

  • 8. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H, Buchdunger E, Meyer T, Mueller M, Furet P.
    J Med Chem; 1997 Oct 24; 40(22):3601-16. PubMed ID: 9357527
    [Abstract] [Full Text] [Related]

  • 9. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW, Palmer BD, Bridges AJ, Showalter HD, Sun L, Nelson J, McMichael A, Kraker AJ, Fry DW, Denny WA.
    J Med Chem; 1996 Feb 16; 39(4):918-28. PubMed ID: 8632415
    [Abstract] [Full Text] [Related]

  • 10. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
    Traxler P, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.
    J Pharm Belg; 1997 Feb 16; 52(2):88-96. PubMed ID: 9193132
    [Abstract] [Full Text] [Related]

  • 11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 12. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
    Traxler PM, Furet P, Mett H, Buchdunger E, Meyer T, Lydon N.
    J Med Chem; 1996 Jun 07; 39(12):2285-92. PubMed ID: 8691423
    [Abstract] [Full Text] [Related]

  • 13. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.
    Panek RL, Lu GH, Klutchko SR, Batley BL, Dahring TK, Hamby JM, Hallak H, Doherty AM, Keiser JA.
    J Pharmacol Exp Ther; 1997 Dec 07; 283(3):1433-44. PubMed ID: 9400019
    [Abstract] [Full Text] [Related]

  • 14. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
    Palmer BD, Trumpp-Kallmeyer S, Fry DW, Nelson JM, Showalter HD, Denny WA.
    J Med Chem; 1997 May 09; 40(10):1519-29. PubMed ID: 9154973
    [Abstract] [Full Text] [Related]

  • 15. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.
    Klutchko SR, Zhou H, Winters RT, Tran TP, Bridges AJ, Althaus IW, Amato DM, Elliott WL, Ellis PA, Meade MA, Roberts BJ, Fry DW, Gonzales AJ, Harvey PJ, Nelson JM, Sherwood V, Han HK, Pace G, Smaill JB, Denny WA, Showalter HD.
    J Med Chem; 2006 Feb 23; 49(4):1475-85. PubMed ID: 16480284
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.
    Dahring TK, Lu GH, Hamby JM, Batley BL, Kraker AJ, Panek RL.
    J Pharmacol Exp Ther; 1997 Jun 23; 281(3):1446-56. PubMed ID: 9190882
    [Abstract] [Full Text] [Related]

  • 17. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.
    Mol Pharmacol; 2008 Feb 23; 73(2):338-48. PubMed ID: 17975007
    [Abstract] [Full Text] [Related]

  • 18. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.
    Vincent PW, Bridges AJ, Dykes DJ, Fry DW, Leopold WR, Patmore SJ, Roberts BJ, Rose S, Sherwood V, Zhou H, Elliott WL.
    Cancer Chemother Pharmacol; 2000 Feb 23; 45(3):231-8. PubMed ID: 10663641
    [Abstract] [Full Text] [Related]

  • 19. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
    Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J.
    Clin Cancer Res; 1997 Nov 23; 3(11):2099-106. PubMed ID: 9815602
    [Abstract] [Full Text] [Related]

  • 20. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
    Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu L, Cui J, Sun L, Wei J, Cherrington JM, Mendel DB.
    Clin Cancer Res; 2001 Dec 23; 7(12):4230-8. PubMed ID: 11751524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.